AR098909A1 - Compuesto heterocíclico - Google Patents
Compuesto heterocíclicoInfo
- Publication number
- AR098909A1 AR098909A1 ARP140104851A ARP140104851A AR098909A1 AR 098909 A1 AR098909 A1 AR 098909A1 AR P140104851 A ARP140104851 A AR P140104851A AR P140104851 A ARP140104851 A AR P140104851A AR 098909 A1 AR098909 A1 AR 098909A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- ring
- alkyl
- optionally
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- -1 trimethylsilylmethyl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 1
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 abstract 1
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 abstract 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 abstract 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052732 germanium Inorganic materials 0.000 abstract 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical group [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000027483 retinoid hormone receptors Human genes 0.000 abstract 1
- 108091008679 retinoid hormone receptors Proteins 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
La presente solicitud se refiere a un compuesto o una sal del mismo que tiene una acción inhibidora de RORᵍt donde ROR es un receptor retinoide. Reivindicación 1: Un compuesto representado por la fórmula [1], caracterizado porque el anillo A es un anillo además opcionalmente sustituido aromático de 6 miembros; R¹ es (1) un grupo representado por la fórmula: -Q(R¹ᵃ)(R¹ᵇ)(R¹ᶜ) en donde Q es un átomo de carbono, un átomo de silicio o un átomo de germanio, y R¹ᵃ, R¹ᵇ y R¹ᶜ son cada uno independientemente un sustituyente, o R¹ᵃ y R¹ᵇ en combinación opcionalmente forman, junto con el Q adyacente, un anillo además opcionalmente sustituido, y R¹ᶜ está unido opcionalmente a un sustituyente para el Anillo A para formar un anillo además opcionalmente sustituido, (2) un grupo neo-pentilo, o (3) un grupo trimetilsililmetilo; R¹¹ es -CR¹²R¹²-R¹², -C(=O)-R⁴ o -SO₂-R¹³; R¹², R¹² y R¹² son cada uno independientemente un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo nitro, un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alquenilo C₂₋₆ opcionalmente sustituido, un grupo alquinilo C₂₋₆ opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido o un. grupo tiocarbamoilo opcionalmente sustituido; R⁴ es un grupo alquilo C₁₋₆ opcionalmente sustituido, un grupo alquenilo C₂₋₆ opcionalmente sustituido, un grupo alquinilo C₂₋₆ opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo acilo, un grupo amino opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo tiocarbamoilo opcionalmente sustituido, un grupo sulfamoilo opcionalmente sustituido, un grupo hidroxi opcionalmente sustituido, un grupo sulfanilo (SH) opcionalmente sustituido o un grupo sililo opcionalmente sustituido, en donde el grupo alquilo C₁₋₆, ₑₗ ᵍʳᵘₚₒ ₐₗqᵘₑₙⁱₗₒ C₂₋₆ ʸ ₑₗ ᵍʳᵘₚₒ ₐₗqᵘⁱₙⁱₗₒ C₂₋₆, el grupo alquilo C₁₋₆ opcionalmente sustituido, el grupo alquenilo C₂₋₆ opcionalmente sustituido y el grupo alquinilo C₂₋₆ opcionalmente sustituido para R⁴ están cada uno opcionalmente sustituidos por 1 a 5 sustituyentes seleccionados de (1) un átomo de halógeno, (2) un grupo nitro, (3) un grupo ciano, (4) un grupo oxo, (5) un grupo hidroxi, (6) un grupo alcoxi C₁₋₆ opcionalmente sustituido por sustituyente/s seleccionado/s de un átomo de halógeno y un grupo carboxi, (7) un grupo ariloxi C₆₋₁₄, (8) un grupo aralquiloxi C₇₋₁₆, (9) un grupo heterocicliloxi aromático de 5 a 14 miembros, (10) un grupo heterocicliloxi no aromático de 3 a 14 miembros, (11) un grupo alquilo C₁₋₆-carboniloxi, (12) un grupo aril C₆₋₁₄-carboniloxi, (13) un grupo alcoxi C₁₋₆-carboniloxi, (14) un grupo mono- o di-alquil C₁₋₆-carbamoiloxi, (15) un grupo aril C₆₋₁₄-carbamoiloxi, (16) un grupo heterociclilcarboniloxi aromático de 5 a 14 miembros, (17) un grupo heterociclilcarboniloxi no aromático de 3 a 14 miembros, (18) un grupo alquilsulfoniloxi C₁₋₆ opcionalmente halogenado, (19) un grupo arilsulfoniloxi C₆₋₁₄ opcionalmente sustituido por grupo/s alquilo C₁₋₆, (20) un grupo alquiltio C₁₋₆ opcionalmente halogenado, (21) un grupo heterocíclico aromático de 5 a 14 miembros opcionalmente sustituido por sustituyente/s seleccionado/s de un grupo hidroxi, un grupo alquilo C₁₋₆, un grupo alcoxi C₁₋₆ y un grupo carboxi, (22) un grupo heterocíclico no aromático de 3 a 14 miembros opcionalmente sustituido por sustituyente/s seleccionado/s de un grupo oxo y un grupo alquilo C₁₋₆, (23) un grupo formilo, (24) un grupo carboxi, (25) un grupo alquil C₁₋₆-carbonilo opcionalmente halogenado, (26) un grupo aril C₆₋₁₄-carbonilo, (27) un grupo heterociclilcarbonilo aromático de 5 a 14 miembros, (28) un grupo heterociclilcarbonilo no aromático de 3 a 14 miembros, (29) un grupo alcoxi C₁₋₆-carbonilo, (30) un grupo ariloxi C₆₋₁₄-carbonilo, (31) un grupo aralquiloxi C₇₋₁₆-carbonilo, (32) un grupo carbamoilo, (33) un grupo tiocarbamoilo, (34) un grupo mono- o di-alquilo C₁₋₆-carbamoilo, (35) un grupo aril C₆₋₁₄-carbamoilo, (36) un grupo heterociclilcarbamoilo aromático de 5 a 14 miembros, (37) un grupo heterociclilcarbamoilo no aromático de 3 a 14 miembros, (38) un grupo alquilsulfonilo C₁₋₆ opcionalmente halogenado, (39) un grupo arilsulfonilo C₆₋₁₄, (40) un grupo heterociclilsulfonilo aromático de 5 a 14 miembros, (41) un grupo alquilsulfinilo C₁₋₆ opcionalmente halogenado, (42) un grupo arilsulfinilo C₆₋₁₄, (43) un grupo heterociclilsulfinilo aromático de 5 a 14 miembros, (44) un grupo amino, (45) un grupo mono- o di-alquilamino C₁₋₆ (el alquilo C₁₋₆ es opcionalmente sustituido por grupo/s carboxi), (46) un grupo mono- o di-arilamino C₆₋₁₄, (47) un grupo heterociclilamino aromático de 5 a 14 miembros, (48) un grupo aralquilamino C₇₋₁₆, (49) un grupo fromilamino, (50) un grupo alquil C₁₋₆-carbonilamino, (51) un grupo (alquil C₁₋₆)(alquil C₁₋₆-carbonil)amino, (52) un grupo aril C₆₋₁₄-carbonilamino, (53) un grupo alcoxi C₁₋₆-carbonilamino, (54) un grupo aralquiloxi C₇₋₁₆-carbonilamino, (55) un grupo alquilsulfonilamino C₁₋₆, (56) un grupo arilsulfonilamino C₆₋₁₄ opcionalmente sustituido por grupo/s alquilo C₁₋₆, (57) un grupo alquilo C₁₋₆ opcionalmente halogenado, (58) un grupo alquenilo C₂₋₆ y (59) un grupo alquinilo C₂₋₆; R¹³ es un sustituyente; el anillo B es un anillo de benceno, un anillo de piridina o un anillo de dihidropiridina, cada uno de los cuales además está opcionalmente sustituido; la estructura parcial representada por la fórmula [2] es CR⁵ᵃ=CR⁶, CR⁵ᵇ=N o C(=O)-NR⁷; R⁵ᵃ y R⁵ᵇ son cada uno independientemente un grupo alquilo opcionalmente sustituido, un grupo alcoxi opcionalmente sustituido, un grupo alquilsulfonilo opcionalmente sustituido, un grupo ciano, un grupo amino cíclico opcionalmente sustituido o un grupo oxetan-3-iloxi; y R⁶ y R⁷ son cada uno independientemente un átomo de hidrógeno o un sustituyente; o el sustituyente que el anillo B opcionalmente además tiene y R⁵ᵃ o R⁵ᵇ en combinación opcionalmente forman el anillo D, en donde el anillo D es un heterociclo que contiene oxigeno de 5 ó 6 miembros que contiene 1 a 2 átomos de oxígeno como heteroátomos además de los átomos de carbono, y está fusionado en la posición formadora del anillo, o R⁵ᵃ y R⁶ en combinación opcionalmente forman el anillo D, en donde el anillo D es un heterociclo que contiene oxígeno de 5 ó 6 miembros que contiene 1 a 2 átomos de oxígeno como heteroátomos además de los átomos de carbono, y está fusionado en la posición formadora del anillo; Y es un grupo metileno opcionalmente sustituido o un átomo de oxígeno; y W es un grupo alquileno C₁₋₂ opcionalmente sustituido; o una sal del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013140210 | 2013-07-03 | ||
PCT/JP2014/067650 WO2015002231A1 (ja) | 2013-07-03 | 2014-07-02 | 複素環化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098909A1 true AR098909A1 (es) | 2016-06-22 |
Family
ID=52143803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104851A AR098909A1 (es) | 2013-07-03 | 2014-12-22 | Compuesto heterocíclico |
Country Status (6)
Country | Link |
---|---|
US (2) | US10053468B2 (es) |
EP (1) | EP3018126A4 (es) |
JP (1) | JP6427491B2 (es) |
AR (1) | AR098909A1 (es) |
TW (1) | TW201602105A (es) |
WO (1) | WO2015002231A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
PE20170267A1 (es) * | 2014-07-01 | 2017-04-12 | Takeda Pharmaceuticals Co | Compuestos heterociclicos y su uso como inhibidores gama-t del receptor huerfano relacionado con retinoide (ror) |
US10000488B2 (en) | 2014-09-11 | 2018-06-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
ES2927631T3 (es) | 2015-12-15 | 2022-11-08 | Astrazeneca Ab | Compuestos de isoindol |
CA3009325A1 (en) * | 2015-12-22 | 2017-06-29 | Takeda Pharmaceutical Company Limited | Tripartite modulators of endosomal g protein-coupled receptors |
JP2020524660A (ja) * | 2017-06-14 | 2020-08-20 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Ror−ガンマモジュレーターとして有用な2,3−ジヒドロイソインドール−1−カルボキサミド |
CN108191633A (zh) * | 2018-01-23 | 2018-06-22 | 辽宁东科药业有限公司 | 一种合成对甲氧基苯乙酸的方法 |
WO2021092242A2 (en) | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Ror gamma t inhibitors and topical uses thereof |
JP2023533123A (ja) * | 2020-05-15 | 2023-08-02 | シャンハイ ライテッド カンパニー リミテッド | RORγ調節剤として使用可能なアニリン化合物 |
CN113387842A (zh) * | 2021-07-08 | 2021-09-14 | 成都泰和伟业生物科技有限公司 | 一种通过OTf胺化合成芳香伯胺的方法 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001938A1 (en) | 1990-07-20 | 1992-02-06 | City Of Hope | Derivatization of c-terminal proline |
DE4211239C2 (de) | 1992-04-03 | 1995-11-16 | Max Planck Gesellschaft | Arzneimittel gegen Herz-Kreislauf-Erkrankungen |
JPH06145169A (ja) | 1992-09-17 | 1994-05-24 | Nippon Soda Co Ltd | 新規な含窒素5員環化合物、その製造方法及び有害生物防除剤 |
JP3601898B2 (ja) | 1996-02-14 | 2004-12-15 | 俊隆 鍋島 | 薬物依存形成抑制剤 |
WO1999006435A1 (en) * | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
US6245746B1 (en) | 1998-01-23 | 2001-06-12 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
WO1999037667A1 (en) | 1998-01-23 | 1999-07-29 | Microcide Pharmaceuticals, Inc. | Efflux pump inhibitors |
JPH11292877A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | 1,4−ジ置換ピリドピラジン誘導体 |
AU6189999A (en) | 1998-10-15 | 2000-05-08 | Bioimage A/S | Specific therapeutic interventions obtained by interference with redistribution and/or targetting |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
ES2313895T3 (es) | 1999-06-14 | 2009-03-16 | Henry Ford Health System | Donadores de oxido nitrico para inducir neurogenesis. |
US7135498B1 (en) | 1999-06-14 | 2006-11-14 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
US7655423B2 (en) | 1999-06-14 | 2010-02-02 | Henry Ford Health System | Nitric oxide donors for inducing neurogenesis |
FR2796947A1 (fr) | 1999-07-30 | 2001-02-02 | Aventis Pharma Sa | Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique |
EP1218003A4 (en) | 1999-09-13 | 2004-02-11 | David M Swope | COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY |
WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
EP1237899A2 (en) | 1999-12-16 | 2002-09-11 | RiboTargets Limited | Nucleic acid compounds and screening assays using the same |
US20030195212A1 (en) | 2000-01-28 | 2003-10-16 | Torbjorn Lundstedt | Novel melanocortin receptor agonists and antagonists |
WO2002009713A2 (de) | 2000-08-01 | 2002-02-07 | Bayer Aktiengesellschaft | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
US20020119978A1 (en) | 2000-12-05 | 2002-08-29 | Swope David M. | Composition and method for decreasing neurologic symptomatology |
DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
US6982274B2 (en) | 2001-04-16 | 2006-01-03 | Eisai Co., Ltd. | 1H-indazole compound |
US20050143388A1 (en) | 2002-01-04 | 2005-06-30 | Michael Chopp | Nitric oxide donors for treatment of disease and injury |
DE60318267T2 (de) | 2002-03-01 | 2008-12-11 | Fujifilm Corp. | Farbphotographisches lichtempfindliches Silberhalogenidmaterial |
DE10224462A1 (de) | 2002-06-03 | 2003-12-11 | Bayer Ag | Verwendung von cGMP stimulierenden Verbindungen |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
US7495016B2 (en) | 2002-10-21 | 2009-02-24 | Irm Llc | Pyrrolidones with anti-HIV activity |
US20060128695A1 (en) | 2002-10-30 | 2006-06-15 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
AU2003276220A1 (en) | 2002-11-13 | 2004-06-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a) |
AU2003296393A1 (en) | 2002-12-30 | 2004-07-29 | Eli Lilly And Company | Factor xa inhibitors |
US20070078144A1 (en) * | 2003-01-29 | 2007-04-05 | Stockwell Brent R | Agents for treating neurodegenerative diseases |
US20060106037A1 (en) | 2003-03-04 | 2006-05-18 | Thomas Bar | Purin-6-one-derivatives |
US7250415B2 (en) | 2003-06-04 | 2007-07-31 | Bristol-Myers Squibb Company | 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors |
CN1566099A (zh) | 2003-06-13 | 2005-01-19 | 中国科学院上海药物研究所 | 异喹啉-1,3,4-三酮类化合物、制备方法及其用途 |
GB2404658A (en) | 2003-08-07 | 2005-02-09 | Bayer Ag | Quinoxalinone derivatives and their use in the treatment of diseases |
WO2005035534A1 (ja) | 2003-10-08 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 複素ビシクロ環および複素トリシクロ環化合物およびその医薬 |
FR2860793A1 (fr) | 2003-10-14 | 2005-04-15 | Entomed | Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations |
JP2005145840A (ja) | 2003-11-12 | 2005-06-09 | Nippon Soda Co Ltd | 縮合ヘテロ環誘導体及び農園芸用殺菌剤 |
PL1697356T3 (pl) | 2003-12-16 | 2008-07-31 | Pfizer Products Incorporated | Pirydo[2,3-d]pirymidyno-2,4-diaminy jako inhibitory PDE 2 |
WO2005058892A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
CN1993347A (zh) | 2004-07-29 | 2007-07-04 | 默克公司 | 钾通道抑制剂 |
WO2006064286A1 (en) | 2004-12-13 | 2006-06-22 | Medivir Uk Ltd | Cathepsin s inhibitors |
BRPI0606379A2 (pt) | 2005-01-05 | 2009-06-23 | Nycomed Gmbh | triazolftalazinas |
US7671050B2 (en) | 2005-01-05 | 2010-03-02 | Nycomed Gmbh | Triazolophthalazines |
US20100150839A1 (en) | 2005-02-04 | 2010-06-17 | Massachusetts Institute Of Technology | Compositions and Methods for Modulating Cognitive Function |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
WO2007020521A1 (en) | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Pyridoyrazinones as pde-5 inhibitors |
JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換2−アミノ縮合複素環式化合物 |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
WO2007146230A2 (en) | 2006-06-14 | 2007-12-21 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
US20110039893A1 (en) | 2006-10-11 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Gsk-3beta inhibitor |
DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
US20090325936A1 (en) | 2006-12-20 | 2009-12-31 | Bilodeau Mark T | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
WO2008121602A1 (en) | 2007-03-29 | 2008-10-09 | Smithkline Beecham Corporation | Chemical compounds |
GB0715103D0 (en) | 2007-08-03 | 2007-09-12 | Lectus Therapeutics Ltd | Calcium ion channel modulators and uses thereof |
PT2190825E (pt) | 2007-08-22 | 2014-07-16 | Irm Llc | Compostos e composições de 5-(4- (haloalcoxi)fenil)pirimidina-2-amina como inibidores de cinases |
US7816540B2 (en) | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
CN101925573A (zh) | 2008-01-29 | 2010-12-22 | 霍夫曼-拉罗奇有限公司 | 新型的n-(2-氨基-苯基)-酰胺衍生物 |
DK2565191T3 (da) | 2008-05-14 | 2014-11-10 | Astellas Pharma Inc | 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati |
AU2009248231A1 (en) | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Novel N-(2-amino-phenyl)-acrylamides |
CA2729581A1 (en) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Fluorinated heteroaryls |
CN102216276A (zh) | 2008-09-11 | 2011-10-12 | 辉瑞大药厂 | 取代的杂芳基物 |
WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
WO2010054260A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases |
ES2453474T3 (es) | 2009-02-06 | 2014-04-07 | Nippon Shinyaku Co., Ltd. | Derivados de aminopirazina y medicamento correspondiente |
US8415333B2 (en) | 2009-02-24 | 2013-04-09 | Respiratorious Ab | Bronchodilating diazaheteroaryls |
AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
WO2011022213A1 (en) | 2009-08-17 | 2011-02-24 | Merck Sharp & Dohme Corp. | Amino tetrahydro-pyridopyrimidine pde10 inhibitors |
EP2485731B1 (en) | 2009-10-06 | 2016-05-11 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as pdk1 inhibitors |
EP2493888B1 (en) | 2009-10-29 | 2016-04-06 | GlaxoSmithKline LLC | Bicyclic pyridines and analogs as sirtuin modulators |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
US20130184462A1 (en) | 2010-09-30 | 2013-07-18 | Council Of Scientific & Industrial Research | Method for predicting and modeling anti-psychotic activity using virtual screening model |
EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
US9512111B2 (en) * | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
US9265735B2 (en) | 2010-11-30 | 2016-02-23 | New York University | Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof |
ES2635030T3 (es) | 2010-12-23 | 2017-10-02 | Merck Sharp & Dohme Corp. | Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2 |
WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
JP5902029B2 (ja) * | 2011-04-28 | 2016-04-13 | 日本たばこ産業株式会社 | アミド化合物およびその医薬用途 |
CN103608347B (zh) | 2011-05-30 | 2016-04-27 | 安斯泰来制药株式会社 | 咪唑并吡啶化合物 |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20140315881A1 (en) | 2011-07-29 | 2014-10-23 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
JP6043290B2 (ja) | 2011-09-22 | 2016-12-14 | 武田薬品工業株式会社 | 縮合複素環化合物 |
ES2699226T3 (es) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
RU2625787C2 (ru) | 2011-11-03 | 2017-07-19 | ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи | Ингибиторы вируса гепатита с, имеющие жесткую вытянутую цепь и содержащие фрагмент { 2-[4-(бифенил-4-ил)-1н-имидазо-2-ил]пирролидин-1-карбонилметил} амина |
DE102011085937B4 (de) | 2011-11-08 | 2017-06-01 | Airbus Operations Gmbh | Leichtbaustruktur, insbesondere Flugzeugprimärstruktur oder untergeordnete Baugruppe, sowie Verfahren zu deren Herstellung |
WO2013100027A1 (ja) | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | 複素環化合物 |
WO2013146963A1 (ja) | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
UA115057C2 (uk) | 2012-04-25 | 2017-09-11 | Такеда Фармасьютікал Компані Лімітед | Азотвмісна гетероциклічна сполука |
WO2013169651A1 (en) * | 2012-05-07 | 2013-11-14 | The University Of North Carolina At Chapel Hill | Direct anti-markovnikov addition of acids to alkenes |
EP2873669A4 (en) | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
JP6411342B2 (ja) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | アミド化合物 |
JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
US20160159808A1 (en) | 2013-07-24 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
EP3029031A4 (en) | 2013-07-30 | 2017-01-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
PE20170267A1 (es) * | 2014-07-01 | 2017-04-12 | Takeda Pharmaceuticals Co | Compuestos heterociclicos y su uso como inhibidores gama-t del receptor huerfano relacionado con retinoide (ror) |
-
2014
- 2014-07-02 JP JP2015525256A patent/JP6427491B2/ja not_active Expired - Fee Related
- 2014-07-02 WO PCT/JP2014/067650 patent/WO2015002231A1/ja active Application Filing
- 2014-07-02 US US14/902,309 patent/US10053468B2/en not_active Expired - Fee Related
- 2014-07-02 EP EP14820366.4A patent/EP3018126A4/en not_active Withdrawn
- 2014-12-12 TW TW103143452A patent/TW201602105A/zh unknown
- 2014-12-22 AR ARP140104851A patent/AR098909A1/es unknown
-
2018
- 2018-07-13 US US16/035,277 patent/US20180319812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201602105A (zh) | 2016-01-16 |
WO2015002231A1 (ja) | 2015-01-08 |
JP6427491B2 (ja) | 2018-11-21 |
US10053468B2 (en) | 2018-08-21 |
US20170050974A1 (en) | 2017-02-23 |
EP3018126A4 (en) | 2016-12-07 |
US20180319812A1 (en) | 2018-11-08 |
EP3018126A1 (en) | 2016-05-11 |
JPWO2015002231A1 (ja) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098909A1 (es) | Compuesto heterocíclico | |
AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
AR111241A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
ES2855732T3 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP | |
AR089807A1 (es) | Compuestos de imidazopirrolidinona | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR092742A1 (es) | Piridinonas antifibroticas | |
CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR098492A1 (es) | Derivados de purina | |
AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
AR098171A1 (es) | Piridinilimidazolonas como herbicidas | |
AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
AR092347A1 (es) | Derivados de azaindol | |
AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
AR113888A1 (es) | Derivados de indol macrocíclicos sustituidos | |
AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |